Since then, combination therapies using the RAF inhibitors vemurafenib, dabrafenib and encorafenib, along with the MEK inhibitors trametinib, cobimetinib and binimetinib or the EGFR inhibitor cetuximab, have gained FDA approvals in subsequent years for other types of cancer, harboring the BRAF V600E mutation [72,73,80]. Here, BRAF is linked to cancer.